Ontology type: schema:ScholarlyArticle
2011-05-11
AUTHORSMitsuhiro Hayashi, Yasuhiro Okumura, Tomofumi Osako, Yasuo Toyozumi, Nobuyuki Arima, Hirotaka Iwase, Reiki Nishimura
ABSTRACTBackgroundTrastuzumab demonstrates significant clinical benefits in HER2-positive metastatic breast cancer (MBC), and recent clinical trials suggest that trastuzumab should be continued in combination with other chemotherapy beyond progression. There is an urgent need to assess if patients could substantially benefit from continuing trastuzumab-based therapy.MethodsWe reviewed 91 patients with HER2-positive MBC treated with trastuzumab and investigated correlations between survival and clinical response to first trastuzumab-based therapy and biological markers, time to first tumor progression (1st TTP), response rate (RR), estrogen receptor (ER), Ki-67, and p53 overexpression.ResultsWith a median follow-up of 33 months, 76 patients had received two or more lines of consecutive trastuzumab-based therapy. Median 1st TTP was 8.6 months; patients who received trastuzumab with chemotherapy had a longer 1st TTP and better RR than those without chemotherapy. In terms of survival after first progression, patients with a longer 1st TTP (≥8.6 months) had significantly better survival compared with those who had a shorter 1st TTP (24.3 months vs. 15.4 months, P = 0.024), and multivariate analysis revealed that 1st TTP was a significant prognostic factor (HR 0.44, 95% CI 0.23–0.82, P = 0.01). There were no correlations between survival and ER or Ki-67; however, there was a correlation with p53 overexpression (HR 1.92, 95% CI 1.01–3.64, P = 0.045).Conclusions1st TTP is a significant prognostic factor for patients who receive subsequent trastuzumab-based therapy. This factor should be considered when determining the efficacy of continuing trastuzumab or switching to another anti-HER2 therapy beyond progression. More... »
PAGES694-700
http://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1
DOIhttp://dx.doi.org/10.1007/s10147-011-0251-1
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1048218924
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/21556795
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal, Humanized",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Breast Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Progression",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "ErbB Receptors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Follow-Up Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ki-67 Antigen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm Metastasis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prognosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptors, Estrogen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Survival Analysis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Time Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Trastuzumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tumor Suppressor Protein p53",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan",
"Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Hayashi",
"givenName": "Mitsuhiro",
"id": "sg:person.01312032020.64",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312032020.64"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Okumura",
"givenName": "Yasuhiro",
"id": "sg:person.01166616331.89",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166616331.89"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Osako",
"givenName": "Tomofumi",
"id": "sg:person.01175256736.52",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175256736.52"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Toyozumi",
"givenName": "Yasuo",
"id": "sg:person.01016230102.90",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016230102.90"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Arima",
"givenName": "Nobuyuki",
"id": "sg:person.016542450374.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.274841.c",
"name": [
"Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Iwase",
"givenName": "Hirotaka",
"id": "sg:person.01117473535.84",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117473535.84"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan",
"id": "http://www.grid.ac/institutes/grid.415532.4",
"name": [
"Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
],
"type": "Organization"
},
"familyName": "Nishimura",
"givenName": "Reiki",
"id": "sg:person.013173055502.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.onc.1202132",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031382266",
"https://doi.org/10.1038/sj.onc.1202132"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10147-006-0601-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001769831",
"https://doi.org/10.1007/s10147-006-0601-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/bcr1536",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016960147",
"https://doi.org/10.1186/bcr1536"
],
"type": "CreativeWork"
}
],
"datePublished": "2011-05-11",
"datePublishedReg": "2011-05-11",
"description": "BackgroundTrastuzumab demonstrates significant clinical benefits in HER2-positive metastatic breast cancer (MBC), and recent clinical trials suggest that trastuzumab should be continued in combination with other chemotherapy beyond progression. There is an urgent need to assess if patients could substantially benefit from continuing trastuzumab-based therapy.MethodsWe reviewed 91 patients with HER2-positive MBC treated with trastuzumab and investigated correlations between survival and clinical response to first trastuzumab-based therapy and biological markers, time to first tumor progression (1st TTP), response rate (RR), estrogen receptor (ER), Ki-67, and p53 overexpression.ResultsWith a median follow-up of 33\u00a0months, 76 patients had received two or more lines of consecutive trastuzumab-based therapy. Median 1st TTP was 8.6\u00a0months; patients who received trastuzumab with chemotherapy had a longer 1st TTP and better RR than those without chemotherapy. In terms of survival after first progression, patients with a longer 1st TTP (\u22658.6\u00a0months) had significantly better survival compared with those who had a shorter 1st TTP (24.3\u00a0months vs. 15.4\u00a0months, P\u00a0=\u00a00.024), and multivariate analysis revealed that 1st TTP was a significant prognostic factor (HR 0.44, 95% CI 0.23\u20130.82, P\u00a0=\u00a00.01). There were no correlations between survival and ER or Ki-67; however, there was a correlation with p53 overexpression (HR 1.92, 95% CI 1.01\u20133.64, P\u00a0=\u00a00.045).Conclusions1st TTP is a significant prognostic factor for patients who receive subsequent trastuzumab-based therapy. This factor should be considered when determining the efficacy of continuing trastuzumab or switching to another anti-HER2 therapy beyond progression.",
"genre": "article",
"id": "sg:pub.10.1007/s10147-011-0251-1",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1312225",
"issn": [
"1341-9625",
"1437-7772"
],
"name": "International Journal of Clinical Oncology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "6",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "16"
}
],
"keywords": [
"trastuzumab-based therapy",
"metastatic breast cancer",
"HER2-positive metastatic breast cancer",
"first tumor progression",
"significant prognostic factors",
"estrogen receptor",
"response rate",
"prognostic factors",
"p53 overexpression",
"breast cancer",
"Ki-67",
"tumor progression",
"human epidermal growth factor receptor",
"anti-HER2 therapy",
"recent clinical trials",
"predictors of efficacy",
"significant clinical benefit",
"better response rate",
"terms of survival",
"epidermal growth factor receptor",
"growth factor receptor",
"clinical response",
"first progression",
"clinical benefit",
"clinical trials",
"better survival",
"patients",
"trastuzumab",
"multivariate analysis",
"therapy",
"biological markers",
"chemotherapy",
"progression",
"more lines",
"factor receptor",
"TTP",
"survival",
"cancer",
"months",
"receptors",
"efficacy",
"overexpression",
"urgent need",
"BackgroundTrastuzumab",
"MethodsWe",
"factors",
"trials",
"ResultsWith",
"treatment",
"correlation",
"predictors",
"markers",
"response",
"benefits",
"time",
"rate",
"need",
"combination",
"lines",
"analysis",
"terms"
],
"name": "Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer",
"pagination": "694-700",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1048218924"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10147-011-0251-1"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"21556795"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10147-011-0251-1",
"https://app.dimensions.ai/details/publication/pub.1048218924"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:11",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_542.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s10147-011-0251-1"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1'
This table displays all metadata directly associated to this object as RDF triples.
259 TRIPLES
22 PREDICATES
109 URIs
98 LITERALS
26 BLANK NODES